Your session is about to expire
← Back to Search
CGC Therapy for Bladder Cancer (CGC Trial)
CGC Trial Summary
This trial is testing a new combination of drugs to treat bladder cancer that has not responded to other treatments. The goal is to find the highest dose of the drugs that can be given without causing serious side effects. Up to 24 patients will be enrolled.
CGC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCGC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2017 Phase 2 trial • 85 Patients • NCT01757171CGC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- All visible bladder cancer has been surgically removed and its stage confirmed.I have a history of bladder reflux or currently have a urinary stent.My bladder cancer is confirmed and not spread into the muscle.My cancer came back after standard bladder treatment.You have had a very bad allergic reaction to drugs containing polysorbate 80 in the past.My bladder cancer has not responded to BCG treatment or has come back.My condition worsened within 18 months after my last BCG treatment.I haven't received any clinical trial treatments in the last 6 weeks.My organ and bone marrow functions are not meeting certain health standards.I am eligible for but refusing or cannot undergo major bladder surgery due to other health issues.I am not currently on any chemotherapy treatments.I am capable of becoming pregnant and have a negative pregnancy test.I have been diagnosed with another cancer within the last 6 months.I am not pregnant or breastfeeding.I am not taking strong drugs that affect liver enzymes.I've had a severe allergic reaction to docetaxel.I haven't had experimental bladder treatments in the last 6 weeks.I am mostly active and can care for myself, even if I can't have surgery due to other health issues.I am over 18 and can understand and sign the consent form.
- Group 1: Gem and Low Cab
- Group 2: Gem and High Cab
- Group 3: Gem, High Cab, and Low Cis
- Group 4: Gem, High Cab, Mod Cis
- Group 5: Gem, High Cab, High Cis
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What therapeutic benefits does Cabazitaxel offer?
"Cabazitaxel is a therapeutic agent used to treat neoplasm metastasis, advance directives, and urinary bladder dysfunction."
Is this research protocol open to participants at the moment?
"Clinicaltrials.gov reveals that this clinical trial is actively recruiting individuals since it was initially posted on December 1st, 2014 and recently updated on February 3rd 2022."
What is the current maximum capacity for participants in this experiment?
"Correct. Clinicaltrials.gov data indicates that this research endeavour, which was first posted on December 1st 2014, is actively soliciting participants to take part in the study. 51 individuals need to be enrolled from a single medical site."
Could you provide details of other investigations that have been conducted with Cabazitaxel?
"Presently, there are 992 studies related to Cabazitaxel with 338 of them currently in Phase 3. Most trials for this medication take place in the city of Shanghai; however, it is also being tested at 53600 other sites around the world."
Share this study with friends
Copy Link
Messenger